publicações selecionadas
- Corrigendum to -Nitazoxanide superiority to placebo to treat moderate COVID-19 - A Pilot prove of concept randomized double-blind clinical trial.- [EClinicalMedicine 37 (2021) 100981]
- Nitazoxanide superiority to placebo to treat moderate COVID-19 - A Pilot prove of concept randomized double-blind clinical trial.
- Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial
- IMUNOTERAPIA ANTI-HIV BASEADA EM CELULAS DENDRÍTICAS: ANÁLISE FENOTÍPICA E RESPOSTA IMUNE CELULAR PÓS-VACINAL
